

Relationship Between Residual Mitral Regurgitation and Clinical and Functional Outcomes in the COAPT Trial

Saibal Kar, Michael J. Mack, JoAnn Lindenfeld,
William T. Abraham, Neil J. Weissman and Gregg W.
Stone, on behalf of the COAPT Investigators

COAPT (NCT01626079) is funded by Abbott

Saibal Kar, MD


Disclosure Statement of Affiliations/Financial Relationship

- Grant/Research Support
Abbott Vascular, Boston Scientific, Gore Medical, Edwards Lifesciences
- Consulting Fees/Honoraria
Abbott Vascular, Boston Scientific, Gore Medical
- Other Financial Benefit
Valcare

- In the COAPT trial treatment of selected patients with heart failure and severe secondary MR with the MitraClip improved 2-year survival, reduced HF hospitalizations (HFH), and improved quality of life compared with maximally-tolerated guideline-directed medical therapy (GDMT) alone
- In addition, the MitraClip was substantially more effective than GDMT alone in reducing MR


Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation

A parallel-controlled, open-label, multicenter trial in ~614 patients with heart failure and moderate-to-severe (3+) or severe (4+) SMR (US ASE criteria) who remained symptomatic despite maximally-tolerated GDMT and CRT if appropriate




*Stratified by cardiomyopathy etiology (ischemic vs. non-ischemic) and site


All Hospitalizations for HF



All-Cause Mortality



MR Reduction in COAPT¹




- Although the MitraClip was more successful in reducing MR than GDMT alone, the mechanistic relationship between MR reduction and the observed clinical and functional outcomes in the COAPT trial is uncertain:
 - Whether achieving 2+ MR has as favorable a prognostic impact as $\leq 1+$ MR is unknown; and
 - Whether MR reduction with GDMT alone has the same durability and prognostic impact as MR reduction by the MitraClip is unknown

- The objective of the present study was to evaluate the durability and impact of the degree of residual MR at 30 days on long-term clinical and functional outcomes in patients enrolled in the COAPT trial, including both the treatment (MitraClip + GDMT) and the control (GDMT alone) groups

Time to First HFH or All-Cause Mortality

Pooled (MitraClip and Control) Population Stratified by 30-day Residual MR



At Risk


MR 0/1+	223	192	152	117	73
MR 2+	122	101	81	57	36
MR 3+/4+	189	120	83	51	30

Time to First HFH or All-Cause Mortality

Randomization Groups Stratified by 30-day Residual MR

MitraClip + GDMT


$P_{int}=0.93$



At Risk

MR 0/1+	202	176	139	106	66
MR 2+	55	45	37	31	21
MR 3+/4+	20	13	7	7	4


GDMT Only



At Risk

MR 0/1+	21	16	13	11	7
MR 2+	67	56	44	26	15
MR 3+/4+	169	107	76	44	26


Cumulative Heart Failure Hospitalization Rate



At Risk

MR 0/1+	223	211	177	138	92
MR 2+	122	109	96	67	48
MR 3+/4+	189	164	133	90	54

All-Cause Mortality




At Risk

MR 0/1+	223	211	177	138	92
MR 2+	122	109	96	67	48
MR 3+/4+	189	164	133	90	54

MitraClip + GDMT


$P_{int}=0.72$



At Risk

MR 0/1+	202	191	161	124	82
MR 2+	55	48	45	36	27
MR 3+/4+	20	19	15	11	7

GDMT Only



At Risk


MR 0/1+	21	20	16	14	10
MR 2+	67	61	51	31	21
MR 3+/4+	169	145	118	79	47

Time to All-Cause Mortality

Randomization Groups Stratified by 30-day Residual MR


MitraClip + GDMT

$P_{int}=0.55$



# At Risk					
MR 0/1+	202	191	161	124	82
MR 2+	55	48	45	36	27
MR 3+/4+	20	19	15	11	7

GDMT Only



# At Risk					
MR 0/1+	21	20	16	14	10
MR 2+	67	61	51	31	21
MR 3+/4+	169	145	118	79	47

KCCQ Improvement @ 12-Month Stratified by 30-Day MR

Mean $\pm$ SE (ANCOVA Model)

$P_{int}=0.71$

Pooled Population


P=0.92 for 0/1+ vs 2+
P=0.15 for 0/1+ vs 3+/4+
P=0.10 for 2+ vs 3+/4+


MitraClip + GDMT


P=0.41 for 0/1+ vs 2+
P=0.37 for 0/1+ vs 3+/4+
P=0.21 for 2+ vs 3+/4+

GDMT Only

P=0.71 for 0/1+ vs 2+
P=0.24 for 0/1+ vs 3+/4+
P=0.21 for 2+ vs 3+/4+







- In the COAPT trial, lower residual MR ($\leq 2+$) at 30 days in both the MitraClip and GDMT groups was strongly associated with reduced HFH, all-cause mortality and improved quality of life compared with residual MR of 3+/4+.
 - This finding suggests that the greater reduction of MR with the MitraClip compared with GDMT alone underlies the observed clinical benefits from the MitraClip.
- There was no significant difference between achieving 0/1+ and 2+ residual MR on improvements in HFH, all-cause mortality and quality of life at 2 years
- While some pts with GDMT had improved MR at 30 days, many of these pts later had recurrent severe MR. The improvement in MR achieved at 30 days with the MitraClip was significantly more durable